Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

Arcus Biosciences Announces New Employment Inducement Grants


Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company's Board of Directors granted fifteen new employees options to purchase a total of 49,650 shares of the Company's common stock at an exercise price per share of $19.08, which was the closing price on May 23, 2022, and restricted stock units to acquire a total of 21,725 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2alfa. For more information about Arcus Biosciences' clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.

Inducement PR

Source: Arcus Biosciences


These press releases may also interest you

at 04:50
The Interstitial Cystitis Drugs Market report provides a detailed analysis of the competitive scenario, the pre-and post-COVID-19 impact on businesses, and the market growth across various regions. The interstitial cystitis drugs market size is...

at 04:35
A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Infrared and Thermal Imaging Systems - Global Market Trajectory & Analytics". The report presents fresh...

at 04:00
The European regulatory authorities tend to be moving in a different direction than U.S. Food and Drug Administration (FDA) regarding novel HIF-PH inhibitor agents. Recent Spherix research provides insights from nephrologists across the EU5 regarding...

at 03:45
A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Industrial Radiography Testing - Global Market Trajectory & Analytics". The report presents fresh perspectives...

at 03:35
A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "High Acuity Information Systems - Global Market Trajectory & Analytics". The report presents fresh...

at 03:30
A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Full Body Scanners - Global Market Trajectory & Analytics". The report presents fresh perspectives on...



News published on 24 may 2022 at 16:15 and distributed by: